Skip to main content
Journal cover image

A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program.

Publication ,  Journal Article
Kulasingam, S; Connelly, L; Conway, E; Hocking, JS; Myers, E; Regan, DG; Roder, D; Ross, J; Wain, G
Published in: Sex Health
September 2007

BACKGROUND: The cost-effectiveness of adding a human papillomavirus (HPV) vaccine to the Australian National Cervical Screening Program compared to screening alone was examined. METHODS: A Markov model of the natural history of HPV infection that incorporates screening and vaccination was developed. A vaccine that prevents 100% of HPV 16/18-associated disease, with a lifetime duration of efficacy and 80% coverage offered through a school program to girls aged 12 years, in conjunction with current screening was compared with screening alone using cost (in Australian dollars) per life-year (LY) saved and quality-adjusted life-year (QALY) saved. Sensitivity analyses included determining the cost-effectiveness of offering a catch-up vaccination program to 14-26-year-olds and accounting for the benefits of herd immunity. RESULTS: Vaccination with screening compared with screening alone was associated with an incremental cost-effectiveness ratio (ICER) of $51 103 per LY and $18 735 per QALY, assuming a cost per vaccine dose of $115. Results were sensitive to assumptions about the duration of vaccine efficacy, including the need for a booster ($68 158 per LY and $24 988 per QALY) to produce lifetime immunity. Accounting for herd immunity resulted in a more attractive ICER ($36 343 per LY and $13 316 per QALY) for girls only. The cost per LY of vaccinating boys and girls was $92 052 and the cost per QALY was $33 644. The cost per LY of implementing a catch-up vaccination program ranged from $45 652 ($16 727 per QALY) for extending vaccination to 14-year-olds to $78 702 ($34 536 per QALY) for 26-year-olds. CONCLUSIONS: These results suggest that adding an HPV vaccine to Australia's current screening regimen is a potentially cost-effective way to reduce cervical cancer and the clinical interventions that are currently associated with its prevention via screening alone.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Sex Health

DOI

ISSN

1448-5028

Publication Date

September 2007

Volume

4

Issue

3

Start / End Page

165 / 175

Location

Australia

Related Subject Headings

  • Uterine Cervical Neoplasms
  • Quality-Adjusted Life Years
  • Quality of Life
  • Public Health
  • Papillomavirus Vaccines
  • Papillomavirus Infections
  • National Health Programs
  • Mass Vaccination
  • Markov Chains
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kulasingam, S., Connelly, L., Conway, E., Hocking, J. S., Myers, E., Regan, D. G., … Wain, G. (2007). A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex Health, 4(3), 165–175. https://doi.org/10.1071/sh07043
Kulasingam, Shalini, Luke Connelly, Elizabeth Conway, Jane S. Hocking, Evan Myers, David G. Regan, David Roder, Jayne Ross, and Gerard Wain. “A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program.Sex Health 4, no. 3 (September 2007): 165–75. https://doi.org/10.1071/sh07043.
Kulasingam S, Connelly L, Conway E, Hocking JS, Myers E, Regan DG, et al. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex Health. 2007 Sep;4(3):165–75.
Kulasingam, Shalini, et al. “A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program.Sex Health, vol. 4, no. 3, Sept. 2007, pp. 165–75. Pubmed, doi:10.1071/sh07043.
Kulasingam S, Connelly L, Conway E, Hocking JS, Myers E, Regan DG, Roder D, Ross J, Wain G. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex Health. 2007 Sep;4(3):165–175.
Journal cover image

Published In

Sex Health

DOI

ISSN

1448-5028

Publication Date

September 2007

Volume

4

Issue

3

Start / End Page

165 / 175

Location

Australia

Related Subject Headings

  • Uterine Cervical Neoplasms
  • Quality-Adjusted Life Years
  • Quality of Life
  • Public Health
  • Papillomavirus Vaccines
  • Papillomavirus Infections
  • National Health Programs
  • Mass Vaccination
  • Markov Chains
  • Humans